Biomedical subjects

J Kleeff

Publications and source records attributed to J Kleeff.

76 records · Page 5Linked to original sources

PubMed1996

[Prognosis in pancreatic carcinoma].

Pancreatic cancer is one of the most frequent carcinomas of the human gastrointestinal tract. despite considerable progress in diagnosis, its prognosis has remained unchanged during the last years. Up to now, there is no possibility to screen patients for pancreatic carcinomas, and the symptoms of the disease are uncharacteristic and often misleading. Surgical treatment, with resection of the tumor is the only chance for cure, but for experienced pancreatic surgeons, an advanced tumor stage at the time of operation is a common finding. Large studies reveal the poor prognosis of the disease. Only 20-30% of all patients suffering from pancreatic cancer can be operated with curative intention. In 80-85% of all cases, the tumor has spread into peripancreatic lymph nodes. Thus, mean 5-years survival rates of 3 to 5% are commonly reported, and the median survival time after establishment of diagnosis is 4-6 months. Improvements in surgical technique and postoperative patient's care have led to an impressive decrease in the formerly considerable morbidity and mortality after pancreatic resection. If the tumor can be resected at an early stage and the regional lymph nodes are not involved, median 5-years survival rates of 20-40% are commonly reported. Further approaches include more radical surgical procedures with dissection of the entire peripancreatic region and resection of the upper abdominal blood vessels. Whether this new technique or a combination of operation, radiation and chemotherapy will improve the prognosis of the disease remains unclear. Large clinical trials are necessary to prove these assumptions.

Epidermal Growth Factor↗

PubMedDate not supplied

Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4.

BACKGROUND: Interleukin (IL)-13 and -4 are multifunctional cytokines that bind to specific cell-surface receptors. The aim of this study was to determine whether pancreatic cancer cells express either receptor, and to assess the growth suppressive effects of chimeric proteins composed of a Pseudomonas exotoxin (PE) A mutant (PE38QQR) fused to IL-13 (IL-13-PE38QQR) or IL-4 (IL-4-PE38QQR) in these cells. MATERIALS AND METHODS: Northern and Western blot analysis were used to analyze the expression of IL-4/-13 receptors and the common gamma chain (gamma c) in pancreatic cancer cell lines. MTT growth assays were carried out to assess the effects of IL-4/-13 and IL-4/-13-PE38QQR on cell growth. RESULTS: All 6 pancreatic cancer cell lines examined expressed IL-13R alpha 1 and IL-4R alpha, one cell line expressed IL-13R alpha 2, and 5 pancreatic cancer cell lines expressed gamma c. IL-13 (5 nM) significantly enhanced the growth of 3 cell lines, whereas IL-4 (5 nM) enhanced the growth of 1 cell line. In contrast, IL-13-PE38QQR and IL-4-PE38QQR inhibited the growth of all 6 tested cell lines. There were large variations in the individual sensitivity of the cells, with LD50 values ranging from 100 ng/ml to 5 micrograms/ml for IL-13-PE38QQR and from 20 ng/ml to 10 micrograms/ml for IL-4-PE38QQR. IL-13 and -4 antagonized these inhibitory activities in some, but not all, of the cell lines. CONCLUSIONS: IL-13 and -4 may act as mitogens toward pancreatic cancer cells by activating IL-4- and IL-13-receptors and IL-13- and IL-4-coupled toxins may ultimately have a role in the treatment of pancreatic cancer.

ADP Ribose Transferases↗

PubMedDate not supplied

Chronic pancreatitis: pathogenesis and molecular aspects.

Chronic pancreatitis (CP) is characterized by irreversible morphological and functional alterations of the pancreas presenting clinically with upper abdominal pain as well as exocrine and endocrine insufficiencies. CP is morphologically characterized by pancreatic head enlargement, calcifications of the parenchyma, cysts, and pancreatic stones. The most common etiological factor of CP in Western industrialized countries is alcohol abuse; less common factors include hereditary pancreatitis, CP due to metabolic disturbances, CP due to pancreas divisum or duodenal wall cysts, and idiopathic CP. The molecular alterations leading to the chronic inflammatory process are nor completely understood. Research during the last years, however, has elucidated that a number of growth factors and their receptors are overexpressed in CP, which is thought to contribute to the high degree of pancreatic fibrosis and to the proliferative potential of ductular cells in this disorder. In addition, gene mutations have been detected in a subgroup of CP samples underscoring the pre-malignant potential of CP. In this review we will summarize our current knowledge about pathogenic and molecular aspects of CP.

Chronic Disease↗

PubMedDate not supplied

Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer.

BACKGROUND: Pancreatic cancer is one of the most aggressive cancers, in part due to its insensitivity to most treatment modalities. This resistance towards cytotoxic therapy is thought to be caused--at least in part--by a general resistance of pancreatic cancer cells towards apoptosis. TRAIL-R3 and TRAIL-R4, which belong to the TRAIL receptor family, can inhibit TRAIL-induced apoptosis. PATIENTS AND METHODS: Seven normal pancreatic tissues and 7 pancreatic cancer tissues were analyzed using Northern blotting, Western blotting and immunohistochemistry. RESULTS: TRAIL-R3 mRNA and protein expression were generally weak in pancreatic cancers and normal pancreatic tissues. In contrast, TRAIL-R4 mRNA and protein were expressed at moderate to high levels in human pancreatic cancer tissues, but demonstrated weak to negative expression in the normal pancreas. CONCLUSION: TRAIL-R4 but not TRAIL-R3 levels were significantly different in pancreatic cancer in comparison to the normal pancreas. These findings give new insight into the resistance mechanisms of pancreatic cancer towards TRAIL-mediated apoptosis.

Adult↗